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Introduction
Each year seasonal influenza outbreaks are responsible for 
significant morbidity and mortality resulting in increased 
hospital admissions. The World Health Organisation 
(WHO) estimates that seasonal influenza affects approxi-
mately 5-15% of the population on an annual basis [1]. 
Between 2000 and 2008, influenza along with other acute 
upper respiratory infections accounted for about 44 000 
hospitalisations per year in France and 77000 in Ger-
many [2]. The elderly and persons with comorbid condi-
tions are at highest risk for complications and death dur-
ing these epidemics most likely as a result of decreased 
immune system function [3]. Organisation for Economic 
Co-operation and Development (OECD) estimates that 
between 85-90% of people who die from influenza in 
France and Germany are over 65 years of age. [1]. An-
nual vaccination remains the main public health strategy 
for containing influenza. Among the elderly, vaccination 
against influenza remains a high priority and has been 
shown to be effective in reducing influenza associated 
morbidity and mortality. Consequently, in the US and Eu-
rope most current vaccination programs recommend vac-
cination against influenza in older adults.
There are several factors responsible for the vulnerabil-
ity to influenza seen in the elderly population; the most 
important is the phenomenon of immunosenescence. 
Immunosenescence is a physiological condition result-
ing from advanced age and which is associated with im-
pairments in both innate and adaptive immunity. Conse-
quently, there is a need for adapted vaccines for elderly 
in order to improve immune responses. For the past 60 
years, the so-called “conventional vaccines” (subunit 
and split non adjuvanted vaccines) have accounted for 
the majority of prophylactic vaccines used against influ-
enza [4]. However, these “conventional vaccines” have 
also shown some limitations in effectiveness especially 
in the elderly population and populations affected by 
chronic diseases or immunocompromised. In addition, 
lack of cross protection against some drifted influenza 
strains accounts for some loss of effectiveness. In a ran-
domized controlled trial in persons aged ≥ 60 years the 
efficacy against laboratory-confirmed influenza illness 
was 58% in a season when the vaccine strains were well-
matched to circulating strains [3]. In other studies, per-
formed in 2 following seasons, the vaccine efficacy in 
the elderly ≥ 65 years was 57.11% (1999-2000 season) 
and 45.74% (2000-2001 season) respectively [5, 6]. In 
the search to fill gaps in efficacy of the conventional 
vaccines and boost the immunogenicity of these vac-
cines, in the past few years several new vaccine formula-
tions have been investigated. Since 1997, the virosomal 
adjuvanted vaccine (Inflexal V®, Crucell, Switzerland), 
has been used widely in several European countries and 
has shown good results in terms of tolerability and safe-
ty. In addition, immunogenicity is significantly better 
than seen in “conventional vaccines” [7-10]. This brief 
review discusses the most recent findings on immuno-
genicity and effectiveness of virosomal adjuvanted vac-
cines in the elderly population.
Adjuvant vaccines
Adjuvants have been used in vaccinology for decades. 
Their use has allowed major improvements in the immu-
nogenicity of vaccines with the added benefit of signifi-
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Summary
The World Health Organisation (WHO) estimates that seasonal 
influenza affects approximately 5-15% of the population on an 
annual basis and these outbreaks are responsible for significant 
morbidity and mortality resulting in increased hospital admis-
sions. Annual vaccination remains the main public health strat-
egy for containing influenza. Inactivated influenza vaccines offer 
a great deal of protection against influenza but these vaccines are 
not optimal for older adults due to their waning immunity and 
other factors affecting immunogenicity. Virosomes, stimulate the 
immune system in a similar way as a natural infection and studies 
have shown that the virosomal adjuvanted influenza vaccine is 
immunogenic and safe in different population groups including: 
the elderly, children and immunocompromised subjects. Currently 
available data suggest improved immunogenicity of the virosomal 
adjuvanted vaccine in the elderly and in subjects without protec-
tive antibody as compared to conventional vaccines.
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cantly reducing the amount of antigen needed to produce 
an immune response. They work in several ways: they can 
modify the cytokine network favouring antigen uptake by 
antigen presenting cells and induction of cytotoxic T lym-
phocyte responses, they may prolong antigen release and 
target antigens for presentation by MHC class I or class 
II molecules thus inducing direct immunity against intra-
cellular and extracellular pathogens [11, 12]. Currently 
licensed adjuvants can be classified into 3 main catego-
ries [13]: mineral salts (aluminium hydroxide, alum), oil 
emulsions (MF59, AS03 and AF03) and particulate deliv-
ery systems (virosomes, AS04). The virosomal adjuvan-
ted vaccines are the focus of this discussion.
Virosomal adjuvanted influenza vaccine
Virosomes, also called Immunopotentiating Reconsti-
tuted Influenza Virosomes (IRIVs), are empty influenza 
virus particles deprived of an internal nucleus and genetic 
information. They stimulate the immune system in a 
similar way as a natural infection. They consist of phos-
pholipids which form a continuous, spherical lipid bi-
layer with an aqueous inner compartment, which can be 
loaded with antigens. In addition, hemoagglutinins and 
neuroaminidases are integrated into the bilayer, as does 
a natural influenza virus, but IRIVs do not contain viral 
RNA and viral nucleocapsid proteins [9]. The dimension 
of the virosome (150 nm) is “appetizing” to Antigen Pre-
senting Cells (APC) [14]. The adjuvant property of IRIVs 
results from the particulate structure and from the pres-
ence of biologically active influenza hemagglutinins in 
their membrane [9, 12]. The repetition of antigens on their 
surface sends a strong signal of activation to the B-cells 
which in turn stimulates production of antibodies [15]. 
The HA maintains the fusion activity, binding to the 
APC receptors and mediating the fusion of the virosome 
with membrane of the APC endosome. The processing 
of antigen in 2 different T cellular compartments leads 
to different effects. Antigen processed in the endosome 
leads to its presentation associated with the Major His-
tocompatibility Complex II (MHC II) whereas antigen 
processed in the citosol leads to its presentation in as-
sociation with the Major Histocompatibility Complex I 
(MHC I) [14]. In this way influenza virosomes are able 
to stimulate both the humoral and the cellular immune 
pathways [16-18]. The virosomal adjuvanted vaccine 
does not contain preservatives such as formaldehyde or 
thiomersal and they do not induce anti-phospholipid an-
tibodies [19, 20]. It has the lowest content of ovalbumin 
among other egg-cultivated vaccine, has been approved 
for all age groups and are well tolerated [9, 20, 21].
Immunogenicity and effectiveness  
of influenza vaccines
Vaccine effectiveness refers to the level of protection 
that a vaccine can be expected to achieve under ordinary 
field conditions of a Public Health Program [22]. Effec-
tiveness is affected by the conditions under which the 
vaccine is used as well as the target population and the 
efficacy. It is usually measured in observational studies. 
Vaccine efficacy on the other hand is assessed in control-
led clinical trials [3].
Immunogenicity refers to the ability of a vaccine to in-
duce an immune response (antibody and/or cell-mediated 
immunity) in a vaccinated individual [23]. For influenza 
vaccines a hemagglutination-inhibition antibody titer of 
1/40 is considered a correlate of protection [24].
In 1997, the European Medicines Agency (EMA), whose 
mandate is to evaluate medicines produced by pharma-
ceutical companies for use in the European Union (EU), 
established criteria for safety and immunogenicity of 
vaccines produced for use in the EU. For influenza vac-
cines to be accepted throughout the EU, annual clini-
cal trials must demonstrate immunogenicity and safety 
in at least 50 subjects between 18 and 60 years and in 
50 subjects over 60 years. Vaccines must fulfil at least 
one of the three EMEA criteria for each influenza strain 
contained in the vaccine for both age groups (18-60 and 
over 60). These criteria are defined as follows: a sero-
conversion rate (SC, defined as a ≥ four-fold increase 
in HA inhibition antibody titre to a titre ≥ 1:40) should 
be > 40% for adults and 30% for persons over 60; the 
proportion of seroprotection (SP, defined as HA inhibi-
tion titres ≥ 1:40) should be > 70% for adults and 60% 
for persons over 60, and the increase in Geometric Mean 
Titer (GMT) should be > 2.5 fold for adults and 2 fold 
for persons over 60 [25].
Immunogenicity and effectiveness  
of virosomal adjuvanted vaccines
Since 1997 the virosomal adjuvanted influenza vaccine 
has met the EMA criteria in the annual clinical trials. 
Furthermore studies have been conducted in different 
groups who can benefit from an adjuvanted vaccine, as 
elderly, children and immonocompromised subjects. In 
all these groups the virosomal adjuvanted influenza vac-
cine has shown to be immunogenic and safe [9].
In children of 6-71 months the SP and SC rates for strain 
A/H1N1 were significantly higher after 2 doses (0.25 ml 
or 0.5 ml according to the age group) 4 weeks apart of 
the virosomal adjuvanted vaccine (SP 88.8% and SC 
88.8%) than after the split vaccine (SP 78.3% and SC 
77.5%). Both vaccines were well tolerated [26].
In a follow-up study the same authors evaluated the im-
munogenicity and the cellular immune response of 2 
doses of 0.25 ml compared to 2 doses of 0.5 ml of vi-
rosomal adjuvanted vaccine in children 6-35 months of 
age. Both the treatments met the EMA criteria after 2 
doses and already after the first dose of 0.5 ml EMA cri-
teria were satisfied, in particular SC and GMT increase 
were reached for all three influenza strains and SC for 
2 strains (A/H3N2 and A/H1N1). Also the cytokines 
production was significantly higher in the 0.5 ml group, 
both after the first and the second dose; on the contrary 
no increase in local or systemic adverse events was re-
ported in children who received 2 doses of 0.5 ml [27].
The effectiveness of influenza vaccines also depends 
on the match between the vaccine and the circulating 
strains. The effectiveness of the virosomal adjuvanted 
vaccine was studied in almost 2000 Spanish children (of 
3-14 years of age), 966 subjects received the vaccine and 
985 were included in the non-vaccinated control group. 
The study was carried out during the season 2004-2005, 
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site significantly less frequently than the comparator. 
Also the number of days with medications to treat a vac-
cine related adverse event was significantly lower with 
the virosomal adjuvanted vaccine [39].
In another comparison study, conducted during the same 
season, a conventional split vaccine, a virosomal adju-
vanted and a MF59 adjuvanted vaccine showed to be 
highly immunogenic, safe and well tolerated. A higher 
rate of solicited local symptoms was reported by the 
group who received the MF59 adjuvanted vaccine [40].
Pegliasco et al. demonstrated that the adjuvanted vaccines 
(MF59 and virosomal) induced a higher antibody response 
than whole virus vaccine in institutionalised elderly and 
that there was no significant difference between groups 
that received MF59 and virosomal adjuvanted vaccines 
both 4 and 12 weeks after the immunization [41].
The efficacy of the virosomal adjuvanted vaccine in pre-
venting Influenza Like Illness (ILI) and the safety of the 
concomitant administration of the virosomal adjuvanted 
vaccine and anti-pneumococcal vaccine were investigat-
ed in non-institutionalised subjects. The incidence of ILI 
was significantly higher in the non-vaccinated control 
group (17.3%) than in two vaccinated group (6.6 and 
4.3% in the elderly vaccinated with influenza vaccine 
alone and with influenza plus pneumococcal vaccine 
respectively). The side effects were mild and did not re-
quire medical assistance [42].
In another study the virosomal adjuvanted showed a pro-
tective efficacy of 80.6% in reducing the incidence of 
ILI in elderly [43].
A cost/benefit analysis compared the virosomal adju-
vanted vaccine with the conventional vaccines (split and 
subunit vaccines). The simulation for the influenza vac-
cination campaign in elderly show that the saving for 
the national health system would be of 124 euros and 
108 euros per vaccinated subject using the adjuvanted 
and conventional vaccines respectively [44].
Conclusions
The inactivated vaccines on the market offer a great 
deal of protection against influenza by limiting disease 
severity and reducing the potential for severe disease 
complications but these vaccines are not optimal for 
older adults due to their waning immunity and other 
factors affecting immunogenicity such as comorbid 
conditions. There is a clear need for vaccines which are 
able to evoke the immune response to influenza in the 
elderly population and in those at high risk for severe 
complications.
Currently available data suggest improved immuno-
genicity of the virosomal adjuvanted vaccine in the eld-
erly and in subjects without protective antibody as com-
pared to conventional vaccines. The tolerability profile 
of the virosomal adjuvanted vaccine is comparable with 
the conventional vaccines and better than the MF59 ad-
juvanted vaccine.
Finally, use of virosomal adjuvanted vaccines in vacci-
nation campaigns targeting the elderly population would 
translate into greater savings for the National Health 
System with respect to conventional vaccines.
when the match was not good, nevertheless the vaccine 
showed an effectiveness of 75.1% in preventing cases 
of influenza-like illnesses and of 88.4% in preventing 
laboratory-confirmed cases of influenza [28].
Several studies demonstrated the immunogenicity and safe-
ty of the virosomal adjuvanted vaccine in immonocompro-
mised children [29] and adults [30] as well as in subjects 
with chronic diseases, as diabetes [31], asthma [32], cystic 
fibrosis [33], and decompensate cirrhosis [34].
The humoral and the cellular immune response of the vi-
rosomal adjuvanted influenza vaccine were investigated 
after one month in patients affected by scleroderma. Pro-
tective antibody titres for the three strains were reached 
in 80% of the subjects and the cellular immune response 
(proliferation of specific T CD4+ and CD8+ lymphocytes 
and production of Th1 cytokines) was found in all vac-
cinated subjects. During the study no progression of the 
course of the underlying disease was observed [35].
Immunogenicity and effectiveness  
of virosomal adjuvanted vaccines  
in the elderly population
In many studies, the virosomal adjuvanted vaccines 
have better immunogenicity profiles with respect to 
non-adjuvanted conventional vaccines (whole virus and 
subunit) [36-38].
In a study by Gluck et al. the virosomal adjuvanted in-
fluenza vaccine was compared with an inactivated whole 
vaccine and a subunit vaccine and showed to induce sig-
nificantly higher seroconversion rates (83%, 79% and 
67% for A/H1N1, A/H2N2 and B respectively) than the 
comparators for all three strains. Also increase in GMT 
was significantly greater with the virosomal adjuvanted 
influenza vaccine. At baseline more than 50% of sub-
jects had protective antibody titres before immunisation 
for the A/H3N2 strain and less than 10% of subjects had 
protective antibody titres for the A/H1N1 and B strains, 
seroprotection rate after vaccination was 72% and 54% 
for the A/H1N1 and B strains respectively. This rate was 
significantly superior for the virosomal adjuvanted vac-
cine with respect to the subunit vaccine [36].
In a following study other authors compared the viro-
somal adjuvanted influenza with a subunit vaccine. The 
seroconversion rates for both A/H1N1 and A/H3N2 
strains were significantly higher for the virosomal adju-
vanted vaccine (71 and 94.7% respectively versus 32.3 
and 61.7% in the subunit group, p < 0.005) [37].
In 2005 deBruijn et al. reported that 4 months after the 
immunization with the virosomal adjuvanted vaccine 
the immune response is still at protective levels [38].
The better tolerability profile of the virosomal adjuvan-
ted vaccine with respect to the other adjuvanted influ-
enza vaccine on the market (MF59 adjuvanted influenza 
vaccine) is demonstrated in many studies [39, 40].
In a double blind clinical study performed during the 
influenza season 2002-2003, comparable seroprotec-
tion rates for 3 strains (A/H1N1, A/H3N2 and B) were 
shown after elderly patients (mean age 76) when immu-
nized with Inflexal V® (virosomal adjuvanted vaccine) 
and Fluad® (MF-59 subunit adjuvant vaccine) influenza 
vaccines, but the first vaccine caused pain at injection 
immunogeniCity of a virosomal adJuvanted vaCCine in the elderly
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